Back to Interventions
Substance / Medication

Luspatercept

SNOMED 830158005UMLS C4086553

Overview

Active Ingredient
luspatercept
RxNorm CUI
2262544
Labeler: Celgene CorporationUpdated: 2024-05-17T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Anemia

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Iron

LOINC 2498-4

secondary

Erythrocytes

LOINC 4544-3

primary

Hemoglobin

LOINC 718-7

primary

Clinical Trials

1 trials linked to this intervention

1
Total Trials
1
Recruiting
0
With Results

Recent Trials

A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India

NCT05891249Phase 4Active Not Recruiting85 enrolled
View all 1 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:
Luspatercept for patients with lower-risk myelodysplastic syndromes/neoplasms: a systematic review and meta-analysis.
Alhajahjeh Abdulrahman, Woite Naira Link, Rolles Benjamin et al. · Blood Adv · 2025
PMID: 40966428Meta-AnalysisFull text (PMC)
Efficacy and safety of luspatercept in non-transfusion-dependent β-thalassemia: long-term results from the BEYOND study.
Taher Ali T, Viprakasit Vip, Kattamis Antonis et al. · Blood Adv · 2025
PMID: 40875596RCTFull text (PMC)
Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trial.
Cappellini Maria Domenica, Viprakasit Vip, Georgiev Pencho et al. · Lancet Haematol · 2025
PMID: 39947215RCT
[Luspatercept combined with roxadustat in the treatment of refractory myelodysplastic neoplasms with ring sideroblasts: a prospective, randomized, single-center study].
Lu X Y, Zhang Z X, Liu Z W et al. · Zhonghua Xue Ye Xue Za Zhi · 2025
PMID: 40887418RCTFull text (PMC)
Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial.
Garcia-Manero Guillermo, Santini Valeria, Zeidan Amer M et al. · Adv Ther · 2025
PMID: 40377899RCTFull text (PMC)
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker Uwe, Della Porta Matteo Giovanni, Santini Valeria et al. · Lancet · 2023
PMID: 37311468RCT
Achieving clinically meaningful changes in haemoglobin levels in patients with non-transfusion-dependent β-thalassaemia treated with luspatercept: A post hoc analysis of the phase 2 BEYOND trial.
Musallam Khaled M, Taher Ali T, Porter John B et al. · Br J Haematol · 2026
PMID: 41139985TrialFull text (PMC)
A phase 2 clinical trial of luspatercept in non-transfusion-dependent patients with myelodysplastic syndromes.
Kosugi Hiroshi, Fujisaki Tomoaki, Iwasaki Hiromi et al. · Int J Hematol · 2025
PMID: 39572468TrialFull text (PMC)
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.
Della Porta Matteo Giovanni, Garcia-Manero Guillermo, Santini Valeria et al. · Lancet Haematol · 2024
PMID: 39038479Trial
Splenic iron decreases without change in volume or liver parameters during luspatercept therapy.
Denton Christopher C, Vodala Sadanand, Veluswamy Saranya et al. · Blood · 2023
PMID: 37704579Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Internal Medicine Physician

Internal Medicine

NUCC 207R00000X
Hematology (Internal Medicine) Physician

Internal Medicine — Hematology

NUCC 207RH0000X
Find a Provider

Health Goals

Goals connected through associated conditions

Improve Energy LevelsOptimize Iron and Blood Health

Quick Facts

Type
Substance / Medication
Fully Specified Name
Luspatercept (substance)
SNOMED CT
830158005
UMLS CUI
C4086553
RxNorm CUI
2262544
Labeler
Celgene Corporation

Clinical Data

This intervention maps to 8 entities in the Ltrl knowledge graph.

1
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.